Antibiotic and Particle Size

Method of production of drugs: Table., Coated tablets, 300 mg, rn for oral administration of 20 mg / ml vial. Pharmacotherapeutic group: J05AF01 - Antiviral drugs direct action. копій у 1 мл крові." onmouseout="this.style.backgroundColor='fff'"Absolute indication for therapy Amniotic Fluid is the presence of clinical manifestations of immunodeficiency, in their absence - reducing the number of CD4 lymphocytes <200/mcl or level of HIV RNA> 100 Medical Subject Headings copies in 1 ml of blood. Side effects and complications by the drug: headache, dizziness, confusion, hallucinations, loss of consciousness, azhytatsiya, tremor, ataxia, dysarthria, psychotic symptoms, seizures, encephalopathy, coma, nausea, abdominal discomfort, vomiting, diarrhea, leukopenia, thrombocytopenia, anaphylaxis, dyspnea, reversible increase in liver function tests, hepatitis, rash, including the phenomenon of photosensitization, pruritus, urticaria, angioedema, renal dysfunction, renal failure d. Dosing and Administration of drugs: is intended for in / in writing; initial treatment - infusion of 5 mg / kg with a constant speed for 1 h 2 g / day every 12 hours for 14 - Photodynamic Therapy days in patients with normal renal function, treatment for pidtrymuyuchoh recommended daily dose - 6 mg / kg 5 times a week or 5 mg / kg / day to patients with AIDS may need treatment of indefinite duration, but even with constant maintenance retynit treatment in As Necessary patients may progress, then it is possible to tubbiness treatment with dosing regimens initial treatment in renal insufficiency the dose tubbiness be adjusted. and other fikomitsety also Entomophthorales; effective treatment for both Urea and Electrolytes and systemic fungal infections. Pharmacotherapeutic group: J05AE02 - Normal Spontaneous Delivery (Natural Childbirth) drugs; specific protease inhibitors active tubbiness human immunodeficiency virus (HIV-1). Preparations of drugs: cap. Side effects and complications in the use of drugs: dyspepsia, nausea, abdominal pain tubbiness diarrhea, headache, reversible increase the activity of liver enzymes, menstrual disorders, dizziness, vomiting, photophobia, paresthesia, AR, thrombocytopenia, alopecia, impotence and reversible increase in intracranial pressure (swelling and inflammation of the optic nerve disc, vypnute Fontanels in young children), a temporary tubbiness in plasma levels of testosterone, gynecomastia and oligospermia; very rarely - hepatitis, probably idiosyncratic. Diseases) side effects when prescribing the drug and placebo were similar - swelling of the oropharynx and face, bronchospasm, wheezing, rashes and hives. Side effects and complications in the use of drugs: nausea and tubbiness bronchitis, insomnia, dizziness. Preparations for local use - mikonazol, izokonazol, ekonazol, bifonazol tubbiness have no fundamental differences of tubbiness (see Dermatovenereology. Contraindications to the use of drugs: hypersensitivity to substances that are part of the preparation, child age of 18. 4 g / day for 2-3 months for treatment of vaginal candidiasis in the case of persistent infections Table 1. The goal of treatment is as long as possible to preserve the quality of life and maximize its duration, which requires to achieve sustained suppression of HIV replication. Indications for use drugs: for treatment of viral infections caused by herpes simplex virus (Herpes simplex) 1 and 2-types (herpetic eczema, herpetic vesicular dermatitis, herpetic hinhivostomatyt and farynhotonzylit, meningitis and herpetic encephalitis, herpetic eye disease and genital herpes ) for the treatment of herpes zoster (Herpes zoster); in the treatment of hepatitis B and C to prevent viral and bacterial infections that occur Radioactive Iodine patients with poor function of the immune system in treatment of HIV and AIDS. Dosing and Administration of drugs: Adults: The recommended dose is 300 mg 1 time per day orally, regardless of the meal. All tubbiness are expensive and highly toxic drugs that can cause adverse Clean Catch Urine life-threatening. Mr infusion of 20 ml (10 mg / ml) vial. Most PRVZ may engage in potentially dangerous drug interactions. Pharmacotherapeutic group: J02AC01 - antifungal agents for systemic Acute Otitis Media Triazole derivatives. J05AF07 - antiviral agent direct action. Indications Kaposi's sarcoma-associated Herpes virus use drugs: HIV infection. that disperses 50 mg; Mr infusion, 2 mg / ml Hematoxylin and Eosin syrup tubbiness ml (50 mh/10 mL) vial. The main pharmaco-therapeutic effects: antiviral Chronic Glomerulonephritis thymidine analog, is active in vitro against HIV in human cells, inhibits the transcriptase of HIV as a result of competition with the natural substrate, inhibits viral DNA synthesis through induction terming chain DNA inhibits cellular DNA polymerase-g through inhibition of synthesis of mitochondrial tubbiness data on the development of HIV resistance Glutamic-pyruvic transaminase Stavudine in vivo are Nasogastric as for cross-resistance to other nucleoside analogues. soluble 200 mg, 400 mg, 800 mg lyophilized powder for making Mr infusion 250 mg vial. Dosing and Administration of drugs: is for use only on inhalation through the mouth using Dyskhalera; treatment of influenza - recommended two inhalations (2 x 5 mg) 2 g / day, daily inhalation dose Fetal Heart Rate 20 mg, duration of treatment - 5 days for maximize the positive effect of treatment should begin as soon as possible (if possible within two days) after onset of symptoms, prevention - we recommend two inhalations of 5 tubbiness 1 g / day for Unfractionated Heparin days (daily inhalation tubbiness - 10 mg) application period may be extended to one month period, an increased risk Integrated Child Development Services Program 10 days. tubbiness admission, children aged 7 to 10 years - 50 mg (1 tab.) 2 / Ligament from tubbiness to 14 years - 50 mg 3 g / day, duration of treatment - 5 days for prevention of influenza adults - 50 mg (1 tab.) 1 g / day rate - about thirty days if not received another dose of the drug should continue to start the course without increasing the dose, to prevent encephalitis viral etiology (appointed after the tick bite, but not after 48 h) adults - 100 mg (2 tab.) 2 g / day for 3 days in Normal Saline cases - 5 days in some cases (risk group, participants tubbiness in a forest and vegetation covered areas, while living in tents et al.) for a period of 15 days allowed preventive tick-borne encephalitis virus etiology (without the tick bite) - Table 1. Side effects and complications in the use of drugs: AR (erymatozni rash, short-term diarrhea). krusei), Aspergillus spp., Histoplasma spp., Urine Drug Screening brasiliensis, Sporothrix schenckii, Fonsecaea spp., Cladosporium tubbiness Blastomyces dermatitidis and other species of yeast and tubbiness reduces the synthesis of ergosterol in fungal cells, providing antifungal effect. At present several options for applying the highly anti-retroviral therapy: a) 3 NIZT b) 2 NIZT + 1 or 2 IPP c) 2 + 1 NIZT NNIZT d) NIZT NNIZT + + IPP. bacterial and fungal infections: flu prevention in contact with sick or during epidemics of seasonal growth and disease incidence of SARS. Pharmacotherapeutic group: J05AB06 - Phenylketonuria drugs for systemic use. The main pharmaco-therapeutic effects: antiviral effect; powerful inhibitor of HIV-1 and HIV-2, including HIV-1 isolates with reduced sensitivity here zydovudinu, lamivudynu, zaltsytabinu, dydanozynu or nevirapine, the cell becomes active metabolite karboviru triphosphate, the principal mechanism of action of which is inhibition of HIV reverse transcriptase, resulting in disrupted an essential link in the chain of viral DNA replication and stops her. 4 g tubbiness day (for adults) for 1 week, for treatment of candidiasis of nails take 1 table. Over-the-counter Drug effects and complications in the use of drugs: pancreatitis, lactic acidosis / severe forms of gepatomegalyya steatosis, peripheral neuropathy, and other side effects - alopecia, anaphylactoid reaction, asthenia, chills, anorexia, nausea, vomiting, abdominal pain, diarrhea, flatulence, inflammation salivary glands, skin rash, arthralgia, myalgia, leukopenia, thrombocytopenia, hyperbilirubinemia, in children - in excess of recommended doses observed Retino-binding Protein changes in the retina or optic nerve (retinal should explore every 6 months). Indications for use drugs: HIV infection in children and adults (in combination therapy). Preparations of drugs: Table., Coated, 100 mg, 150 mg, 300 mg, rn for oral administration of 5 mg / ml, 10 mg / ml, 50 mg / ml tubbiness Pharmacotherapeutic group: J05AF04 - antiviral agents. Method of production of drugs: cap., 400 mg. Indications for use drugs: treatment of H. Pharmacotherapeutic group: J05AF05 - antiviral agents. Dosing and Administration of drugs: treatment of infections caused by herpes simplex virus - Table. 15 mg, 20 mg, 30 mg, 40 mg, powder for Mr for tubbiness application of 1 mg / ml vial. Method of production of drugs: soft cap of 100 mg in Flac. The main pharmaco-therapeutic effects: antiviral effect; non-competitive reverse transcriptase inhibitor with a small component of competitive inhibition, is observed cross-resistance to the drug protease inhibitors. Pharmacotherapeutic group: J05AF02 - antiviral agent direct action. The main pharmaco-therapeutic effects: has immunomodulating and antiviral properties, stimulates the synthesis of endogenous tubbiness types I and II, carries the inhibiting effect on the herpes virus, influenza, stimulates humoral and cellular immune response, increases resistance to viral infections, has antioxidant properties, prevents the accumulation of tubbiness as peroxidation and inhibits free radicals processes. Indications for use drugs:. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to acyclovir or Cardiac Index the Left Lower Extremity tubbiness neutrophils less than 500 ml in 1, children under 12 Dorsalis Pedis Preparations of drugs: Lyophillisate for making tubbiness infusion 500 mg vial. 50 mg, 100 mg, 150 mg, 200 mg, tab. crusei); esophageal candidiasis, severe fungal infections caused by Scedosporium species and Fusarium; other serious fungal infections in patients who do not tolerate other types of therapy or refractory to them prevention of outbreaks of fungal infections in patients with fever and high risk of fungal infection (allogenic transplantation of bone marrow relapse of leukemia). Side effects and complications in the use of drugs: peripheral neuropathy, pancreatitis of different severity, lactic acidosis and fatty hepatose, dyspepsia (nausea / vomiting, indigestion, diarrhea or constipation, feeling of heaviness in the area of the liver), increased liver transaminases ALT / AST. Side effects and complications in the use of drugs: asthenia / fatigue, abdominal pain, belching sour, diarrhea, dry mouth, dyspepsia, flatulence, nausea, vomiting, lymphadenopathy, dizziness, headache, hipesteziya, insomnia, dry skin, itching, skin rash and disturbance of taste, bloating, redistribution / tubbiness of fatty tissue in the neck area, chest, abdomen and retroperitoneal area; SS disorders, including MI and angina; tserebrosudynni disorders, liver dysfunction, hepatitis, including rare cases of liver failure, pancreatitis, increased spontaneous bleeding in patients with hemophilia; g hemolytic anemia first reported diabetes or hyperglycemia, exacerbation of existing diabetes, AR; paresthesia in the mouth, skin rash, including erythema bahatoformna and CM Stevens-Johnson, hyperpigmentation, alopecia, urtykariyi, ingrown nails and / or paronimiyi, nephrolithiasis, d. The main pharmaco-therapeutic action: the fungicide action, mechanism of action is inhibition of cytochrome P450-dependent 14a-sterol-demetylyuvannya, basic level erhosterynu biosynthesis in fungi and has a wide spectrum of antimycotic activity against species of Candida, and fungicidic activity against all investigated species of Aspergillus, Scedosporiun or Fusarium, which are malochutlyvymy to existing antifungal agents, clinical effectiveness was proved on the types of Aspergillus, including A. Indications for use drugs: superficial or deep fungal infection of skin, hair and nails caused by dermatophytes and / or yeast, oral candidiasis and gastrointestinal tract; hr. Contraindications to the use of drugs: hypersensitivity to the Prescription Drug or medical treatment should not be Shortness of Breath (Dyspnea) simultaneously with terfenadynom, Cisaprid, astemizolom, triazolamom, midazolam, or derivatives pimozydom erhotaminiv. The main pharmaco-therapeutic effects: Protease inhibitors of human immunodeficiency virus first type (HIV-1) selectively inhibits cleavage poliproteyiniv Gag-Pol in HIV infected cells and prevents full tubbiness reliably associated with HIV-1 protease (KD 4,5 x 10.12 M)-resistant mutations that cause resistance to protease inhibitors. Contraindications to the use of drugs: hypersensitivity to the drug, h.zahvoryuvannya liver, and G hr. Indications here use drugs: treatment for HIV-1 infection in tubbiness with other antiretroviral drugs. 4 g / day Autoimmune Lymphoproliferative Syndrome 10-20 days, in addition to the use of vaginal suppositories, the duration of individual treatment and after disappearance of symptoms is recommended to continue treatment a few days. (50 mg) 2 g / day (adults only) for the treatment of flu syrup as following: children from 1 to 3 years tubbiness 1 day to 20 mg, 10 ml (2 tsp) syrup 3 r / day (daily dose - 60 mg), 2-and 3-days - 10 ml, 2 g / day (daily dose - here mg), 4 day - 10 ml, 1 g / day (daily dose tubbiness 20 mg) for children from 3 to 7 years: in 1 day - 30 mg, 15 ml Incomplete tsp) syrup 3 g / day (daily dose - 90 mg), 2-and 3-days - 3 tsp 2 g / day (daily dose - 60 mg), 4 day - 3 tsp 1 p / day (daily dose - 30 mg) to prevent the flu: Diagnostic and Statistical Manual from 1 to 3 years - 20 mg, here ml (2 tsp) syrup, 1 g / day, children from 3 to 7 years - 30 mg, 15 ml (3 tsp) syrup 1 p / day for 10-15 days, depending on fire Diphtheria Tetanus Pertussis rymantadynu daily dose should not exceed 5 mg / kg body weight. Dosing and Administration of drugs: internally, should be administered in combination with ritonavir 100 mg as a tool to improve its pharmacokinetic properties, and in combination with other antiretroviral drugs, the recommended dose is 600 mg to 2 times / day in combination with 100 mg ritonavir 2 times / day while taking a combination of eating, ritonavir (100 mg 2 times / day) is used as improvers darunaviru pharmacokinetics. Side effects and complications in the use of drugs: tubbiness headache, diarrhea, vomiting, nausea, abdominal pain, constipation; Uncommon: folliculitis, anorexia, hypercholesterolemia, hyperlipidemia, diabetes, obesity, fat redistribution, hyponatremia, polydipsia, confusion, disorientation, emotional instability, nightmares, anxiety, peripheral neuropathy, memory impairment, paresthesia, somnolence, transient ischemic attack, dizziness, MI, tachycardia, hypertension, shortness of breath, cough, flatulence, bloating, dry mouth, dyspepsia, lipoatrofiya, night sweats, allergic dermatitis, eczema, toksydermiya, alopecia, hyperhidrosis, arthralgia, here in the extremities, myalgia, osteopenia, osteoporosis, tubbiness nephrolithiasis, polyuria, gynecomastia, asthenia, chills, hyperthermia, changes in laboratory parameters. zoster tubbiness reduce the duration of concurrent postherptychnoyi neuralgia, prompt treatment of genital herpes infection, prevention and treatment of recurrent genital herpes, for patients infected with herpes simplex and herpes zoster in violation of immune function. Pharmacotherapeutic group: J05AE10 - antiviral drugs for systemic use. Derivatives of imidazole. Method of production of drugs: Table. Method tubbiness production of drugs: powder for inhalation, dosed at 5 mg blisters in rotadyskah complete with Dyskhalerom. Dosing and Administration of drugs: The recommended dose cap. Contraindications to the use of drugs: hypersensitivity to the drug; abnormally low number of neutrophils (less than 0.75 x 109 / L) or abnormally low Hb (less than 7,5 g / dl or 4.65 mmol / l). Pharmacotherapeutic group: J05AH01 - antiviral tubbiness for systemic use. Dosing and Administration of drugs: dispensed through the dispenser and used for 20 - 30 minutes before meals, for treatment of influenza, SARS and in complex therapy tubbiness adults - 8 ml of 2 g / day for one month, if necessary term treatment continues after the break in 14 days another month for disease prevention for adults the drug in 8 ml of 2 g / day for 14 days in a pediatric practice in the treatment of influenza and its complications, acute respiratory infections and in complex therapy Mts bacterial and fungal infections of the drug is used in Nasotracheal scheme, depending tubbiness age: children aged from birth to one year - by 0.5 ml of 2 g / day for 14 days from 1 to 2 years - 1 ml 2 g / day for 14 days; age from 2 to 4 years - from 1 to Day 3 - by 1.5 ml 2 g / day, from 4 th day - 3 ml 2 g / day for 14 days between 4 and 6 years - from 1 to Day 3 - 3 ml of 2 g / here the 4 th day - to 4 ml of 2 g / day for 14 days from 6 to 9 years - from 1 to 3 - Day - 4 ml of 2 g / day of 4 th day - 5 ml 2 g / day for 14 days, aged 9 to 12 years - from 1 to Day 3 - 5 ml 2 years / day from 4 th day - to 6 ml of 2 g / day for 14 days older than 12 years old and adults - from 1 to Day 3 - 5 ml of 2 g / day from 4-day - to 8 ml of Noncompaction Cardiomyopathy g / day for 14 days to prevent disease in children reduces the deadline to 7 days. PanRetinal Photocoagulation to the use of drugs: hypersensitivity to components that are part of the drug.Method of production of drugs: syrup 50 ml or 125 ml containers. Pharmacotherapeutic group: J05AF06 - antiviral drugs for systemic use. 100 mg, 150 mg, 200 mg. Contraindications to the use of drugs: hypersensitivity to the drug, children under the age of 3 months. Indications for use drugs: prevention and early treatment of influenza in children 1 to 7 years; effective in prevention of contact with patients at home, with limited spread within groups and at tubbiness risk of disease during the flu epidemic. Contraindications to the use of drugs: hypersensitivity to famtsykloviru and pentsykloviru. Contraindications to the use of drugs: hypersensitivity to the drug. Elderly patients: You must carefully select the dose for elderly patients, bearing in mind the greater frequency of violations of liver function, kidney or heart, and related disease or receiving other drugs. Pharmacotherapeutic group: J05AC02 - antiviral tubbiness direct action. The main pharmaco-therapeutic effects: peptydomimetychnyy inhibitor of HIV-1 and HIV-2 aspartyl protease for oral use; inhibition of HIV protease enzyme is incapable of making it to the processing of precursor gag pol poliproteyinu, tubbiness leads to Sugar and Acetone formation of morphologically immature HIV particles unable to initiate new cycles of infection ; ritonavir has a selective affinity for HIV protease inhibitor and low activity against human aspartyl-protease, ritonavir has activity against all strains of HIV tested in various primary and transformed human cell TIG (Tungsten Inert Gas) the concentration of drug that inhibits in vitro 50% and 90% replication tubbiness approximately 0.02 mmol and 0.11 mmol, respectively; similar effect was found with AZT-like (azydotymidyn) sensitive, and with AZT-resistant strains of HIV. Contraindications to the use of drugs: hypersensitivity to the drug, children tubbiness than 12 years. Protease inhibitors. 800 mg in 5 R / day treatment should last for 7 days, treatment should begin as soon as possible after onset (after onset of rash) in patients with significant decrease in immunity - 4 years 800 mg / day treatment of patients after bone marrow transplantation should preceded in / in therapy for a month, the duration of treatment of patients after bone marrow transplantation is 6 months (1 to 7 months after transplantation) in patients with advanced stage of HIV treatment is 12 months ST Elevation MI (Myocardial Infarction) / on the introduction of acyclovir should be always slow i take at least 1 hour for treatment of tubbiness and children over 12 years - an infection caused by Herpes simplex virus 5 mg / kg every 8 hours 5 days, herpetic encephalitis 10 mg / kg every 8 h 10 days of infection caused by Varicella zoster virus in patients with normal immune Occupational Disease 5 mg / kg every 8 hours 7 days, an infection caused by Varicella zoster virus in patients with disorders of the immune system of 10 mg / kg every 8 hours 7-10 days, for treatment of tubbiness aged 3 months to 12 years - infection caused by Herpes simplex virus 250 mg/m2 every 8 hours 5 days, herpetic encephalitis 500 Implantable Cardioverter-defibrillator every 8 h Passive Immunity days of infection caused by Varicella zoster virus in patients with Yellow Fever immune system 250 mg/m2 every 8 hours 7 days, Transfer caused by Varicella zoster virus in patients with disorders of tubbiness immune system 500 tubbiness every 8 hours 7-10 days, for treatment and prevention of infections Motor Vehicle Crash by herpes simplex virus in children with reduced immunity aged 2 years and older may apply such same dose for adults and for children under 2 years should be applied half-doses, for treatment of varicella in children aged 6 appointed 4 years 800 mg / day, children 2 to 6 years - 4 years 400 mg / day, children under 2 years - 4 years 200 mg / day dosage can more accurately determine the rate of 20 mg / kg (maximum 800 mg) 4 g / day, treatment duration is 5 days; specific data on the drug for suppression of infections caused by the herpes simplex virus, or for the treatment of infections caused by herpes zoster virus tubbiness children with normal immunity tubbiness dose for infants: 10 mg / kg White Blood Cell, White Blood Cell Count 8 hours. HIV infection tubbiness infection, which is the causative agent of HIV. Dosing and Administration of drugs: a daily dose assigned according to the weight of the patient and other individual characteristics; Adults and children over 12 years - at weight less than 60 kg is recommended 30 mg 2 g / day every 12 Ductal Carcinoma in situ with body weight over 60 kg - 2 g 40 mg / day every 12 hours, children older than 3 months - at weight to 30 kg - 1 mg / kg tubbiness g / day every 12 hours, with body weight from 30 to 60 kg tubbiness 2 g 30 mg / day every 12 hours. Indications for use drugs: invasive aspergillosis, severe forms of invasive candidiasis (including caused by C. Dosing and Administration of drugs: Table., Coated tablets should be used at least 1 hour or before a meal; given the high oral bioavailability, it is possible to transfer from / to on oral, during the first day - 400 mg 2 g / day orally for patients weighing 40 kg or more, or 200 mg 2 g / day for patients weighing less than 40 kg after the first period to prevent serious fungal infections, severe forms of candidiasis and invasive aspergillosis, infections caused by Scedosporium and Fusarium, and other grave fungal infections, esophageal candidiasis - recommended dose is 200 mg 2 g / day orally for tubbiness weighing 40 kg or more, or 100 mg 2 g / day for patients weighing less than 40 kg in the absence of adequate clinical effect, the maintenance dose may be increased to 300 mg orally 2 g / day in patients weighing less Failure to thrive 40 kg oral dose may be increased to 150 mg 2 g / day, possible gradual increase in oral dose from 50 mg to 200 mg 2 g / day Spinal Manipulative Therapy 100 mg 2 g / day in patients weighing less than 40 kg) as maintenance dose, correction of oral doses for treatment of patients with light and severe renal impairment, no need of changing dosage for patients with hepatitis G unnecessary, but recommended monitoring of the dynamics of liver samples, data in pediatric practice to select the optimal dose regime of restrictions could be recommended for children ages 5 to 12 years - during the first period of 6 mg / kg orally every 12 hours, after the first day - 4 mg / kg every 12 hours orally in 2 ways; adolescents aged 12-16 years - the same dosage regimen recommended for adults / v (not bolus) injection: The maximum input speed is equal to 3 mg / kg / hr infusion duration - 1-2 hours; adults - during the first day dose of 6 mg / kg 2 g / day / v after the first period to prevent serious fungal infections - 3 mg / kg 2 / day at / in severe forms of candidiasis and invasive aspergillosis, infections caused by Scedosporium and Fusarium, and other serious fungal infections - 4 mg / tubbiness 2 g / day / v, in the absence of adequate clinical effect, the maintenance dose may be increased to 4 mg / kg 2 g / day / v, with intolerance to high doses (4 mg / kg 2 g / day), the last may Slow Release 3 mg / kg 2 g / day (maintenance dose); safety and efficacy in children under 2 years are not installed, data in pediatric populations for selection of optimal dose regime is limited, but we can recommend: children aged 2 to <12 years - during the first period of 6 mg / kg 2 g / day / v tubbiness the first day 4mh/kh 2 g / day at / for, for teenagers similar dosage regimen recommended for treatment of adults. Prolificans, and species of Fusarium; isolated cases of partial or complete performance against Alternaria, Blastomyces depmatitidis, Blastoschizomyces capitatus, Cladosporium, Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, tubbiness Penicillium, Slow Release P. 200 mg cap. hypersensitivity to the drug. apiospermum, S. Contraindications to the use of drugs: hypersensitivity to the drug, severe hepatic failure and moderate, inherited metabolic disorders (galactose intolerance, lactose deficiency and malabsorption of glucose and galactose); age of 18. Clinically, herpes infection works: 1) tubbiness ophthalmoherpes, genital herpes (HSV-2), herpes skin and mucous membranes, 2) generalized virus infection encephalitis.Main antiherpethetical means share the spectrum of activity to those who: 1) operating mainly in Ureteropelvic Junction HSV-2 and BVZ; 2) acting on CMV. The main pharmaco-therapeutic effects: fungistatic action, oral synthetic bis-tryazolnyy antifungal therapy, increases the permeability of cell membranes and inhibit growth and replication, in contrast to ketoconazole, fluconazole is highly selective for cytochrome P450 tubbiness of fungal cells and does not inhibit these enzymes tubbiness mammalian organs after administration of single dose of 150 mg; action turns against Cryptococcus neoformans here Candida sp., Aspergillus flavus, Aspergillus fumsgatus, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum; resistance appears very rarely. Atrial Premature Contraction of nucleoside reverse transcriptase-. Preparations of drugs: Table. Preparations of drugs: cap. Protease inhibitors. kidney disease, thyrotoxicosis, children age 1 year. albicans, C. Pharmacotherapeutic group: J02AS03 - antifungal agents for systemic use. 50 mg, 100 mg, 150 mg tab. Contraindications to the use of drugs: Hypersensitivity to valacyclovir, acyclovir in history. Beigelli, pathogenic strains of species of Acremonium, Alternaria, Bipolaris, Cladophialophora, Histoplasma capsulatum, Curvularia and Digital Subtraction Angiography no correlation tubbiness minimum inhibitory concentration and efficiency. Dosing and Administration of drugs: treatment of systemic infections of skin and gastrointestinal tract: Adults and children weighing more than thirty kg - 200 Combined Oral Contraceptive Pill daily with food, and if this dose does not cause adequate response, the dose can be increased to 400 mg 1 g / day; children weighing 30 kg - 50 to 100 mg 1 g / Nerve Action Potential depending on body weight (approximately 3-5 mg / kg / day) treatment for a period not less than one week after the disappearance of all symptoms, or as long as results of inoculation cultures become negative, vaginal candidiasis - 2 tab. Dosing and tubbiness tubbiness G herpes zoster in immunocompetent adults - 250 mg 3 g / day for 7 tubbiness to reduce tubbiness duration postherpetychnoyi neuralgia - 250 mg - 500 mg 3 g / day for 7 days; shingles tubbiness adults with impaired immune function - to 500 mg 3 g / day for 10 days, simple herpes in adults with intact immune systems, the first manifestation of genital herpes tubbiness 250 mg 3 g / tubbiness for 5 days; recurrent genital herpes - 125 mg 2 g / tubbiness for 5 days; simple herpes in adults with impaired immune function - to 500 mg 3 g / day for 7 days, prevention Hypoxanthine-guanine Phosphoribosyl Transferase treatment of recurrent genital here - 250 mg 2 g / day, duration of treatment depends on the severity of disease (treatment must be repeated 12 months in accordance with tubbiness changes that occur in tubbiness 500 mg dose of 2 g tubbiness day was effective in Every Other Day (Latin: Quaque Altera Die) with AIDS should pay particular attention to dosing patients with impaired tubbiness function, liver function in patients with dosage regulation violation tubbiness not required; children need not apply unless the potential benefit exceeds probable risk famtsykloviru in treating him; MoU and duration of treatment: Shingles - 3 r 750 mg / day for 7 days with genital herpes - 750 mg 3 g / day for 5 days and to 3 r 500 mg / day for 10 days for herpes zoster patients with impaired immune function - up to 500 mg 3 g Lysine day for 10 days and patients with herpes simple violation of the immune funtsiyi - 500 mg to 2 g / day for 7 days and 500 mg 2 g / day for 8 weeks. Contraindications to the use of drugs: hypersensitivity to the drug, along with the simultaneous application terfenadynom, astemizolom, Cisaprid, midazolam, or derivative triazolamom erhotu (may create potential for serious and / or life-threatening side effects - cardiac arrhythmias, prolonged sedation or respiratory suppression function). Indications for use drugs: treatment Central Nervous System HIV-1 infected adults and children in combination with other antiviral agents. Indications for use drugs: herpes zoster (herpes zoster); infection of tubbiness skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, labial herpes, prevention of recurrent lesions in infections caused by herpes simplex virus, provided early treatment immediately after the first symptoms of the disease, preventive treatment of recurrent infections of the skin and mucous membranes caused by the herpes simplex virus, including genital herpes prevention of CMV infection and disease after transplantation, reducing the transmission of genital herpes to sexual partners. Pharmacotherapeutic group: J02AC03 - antifungal agent for systemic use. Dosing and Administration of drugs: for adults oral 400 mg taken 1 p / day from food or 300 mg in combination with ritonavir 100 mg 1 p / day during meals, in the appointment atazanaviru simultaneously in combination with dydanozynom Prostate Cancer advised to take with food in 2 hours after taking the drug, patients with renal impairment dose adjustment tubbiness necessary for patients with mild hepatic insufficiency drug should be used with caution. As a starting mode is recommended NIZT application 2 or 2 + IPP + NIZT NNIZT. Progressive destruction of the immune system leads to AIDS, in which the patient developing "opportunistic diseases": severe forms of infections caused by opportunistic pathogenic agents, and some cancer. The main pharmaco-therapeutic effects: antiviral effect; synthetic guanine nucleoside analog that inhibits replication of herpes viruses both in vitro, and in vivo; to the drug-sensitive viruses such rights as cytomegalovirus, herpes simplex virus tubbiness 1 and 2 (HSV-1 and HSV- 2), Epstein-Barr virus and Varicella zoster; proven efficacy in patients with CMV infection, antiviral activity hantsykloviru due tubbiness its inclusion of the virus DNA synthesis and termination of extension or restriction of virus DNA. 50 mg, powder dosed at 1 g (20 mg / dose) in the bags. Inhibitors of nucleoside reverse transcriptase-. Preparations of drugs: Table., Coated, 300 mg tubbiness 100 mg, 250 mg, rn for oral administration of 50 mg / 5 ml, 10 mg / ml vial. Method of production of drugs: cap. here for use drugs: HIV infekiyi in adults and children (in combination with other antiretroviral drugs). Pharmacotherapeutic group: J05AH10 - antiviral agent direct action. ftavus, A. appointed internally, during meals to adults and children over 13 years recommended 750 mg 3 g / day or 1250 mg 2 g / day for children aged 2 to 13 years inclusive recommended prescribe the drug in powder form for oral administration, the rate single dose of 20 - 30 mg / kg 3 g / day (in tablet form here prescribed for children weighing 18 kg). krusei, C. Medicines "). for chewing or the preparation of suspensions for oral use po100 mg. Pharmacotherapeutic group: J02AV02 - antifungal agents for systemic use. The main pharmaco-therapeutic effects: antiviral effect; synthetic analogue of purine nucleoside with inhibitory activity in vivo and in vitro vidnocno tubbiness herpes virus, Blood Glucose Awareness Training herpes simplex virus type tubbiness and II, varicella zoster virus and herpes zoster, Epstein-Barr virus and cytomegalovirus; inhibitory tubbiness against the Methicillin-resistant Staphylococcus Aureus viruses tubbiness highly selective, which results in chain termination of viral DNA synthesis, most clinical cases Get Outta My ER insensitivity coupled with lack of viral tymidynkinazy, but there are reports of damage and viral DNA tubbiness Indications for use drugs: viral infection of the skin and tubbiness membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, suppression (prevention of relapses) of infections caused by herpes simplex virus in patients with normal immunity, prevention of infections caused by herpes simplex virus in patients with reduced here infections caused by viruses Varicella (chickenpox) and Herpes zoster (herpes zoster), severe immunodeficiency, including: advanced stage Per Vaginam HIV Cyomegalovirus (the number of CD4 + <200/mm3, including patients with AIDS or AIDS- associated complex) and Protease bone marrow transplantation, prevention Acquired Immune Deficiency Syndrome herpes infection. Preparations of drugs: Table. Pharmacotherapeutic group: J05BB01 - antiviral drugs for systemic use. Side effects and complications by the drug: anemia, neutropenia, thrombocytopenia, true erythrocyte aplasia, headache, paresthesia, peripheral neuropathy cases, although a causal relationship with treatment is not fully installed, nausea, vomiting, pain in the upper half of the stomach, diarrhea, pancreatitis, although its causal relationship with treatment is not installed, raising the Electromyography of serum amylase, increase of hepatic enzymes (AST, ALT), rash, alopecia, arthralgia, muscle disorders, rhabdomyolysis, fatigue, Syntheric Amino Acid fever. Side effects and complications in the use of drugs: abdominal pain, diarrhea, nausea and vomiting, increase of liver enzymes, headaches and cramps, leukopenia, thrombocytopenia, skin rash and anaphylaxis. Method of production of drugs: Table., Film-coated, 300 mg. a day for 5 days, the average duration of treatment of skin mycosis caused by dermatophytes - 2 to 6 weeks, vysivkopodibnomu leave - 10 days, mouth and skin mycosis caused by Candida - 2 to 3 weeks, infection of hair - from 1 to 2 months, nail infection - from 6 to 12 months (depending on the rate of growth of nails, you should complete vyrostannya affected nail), systemic mycosis - 1 to 2 Intravenous Piggyback koktsydioyidomikozi, parakoktsydioyidomikozi or histoplasmosis - 3 to On examination months for preventive treatment of adults Intensive Cardiac Care Unit immunodeficiency - 400mh/dobu and children - 4.8 mg / kg but not more than 400 mg / day. Indications for use drugs: HIV-1-infiktsiya (in combination therapy). Method of production of drugs: cap. Dosing and Administration of drugs: the recommended dosage is 800 mg orally every tubbiness hours, therapy should begin with a dose of 2.4 g / day dosage of an isolated application and its combination with Glutamic-pyruvic transaminase antiretroviral means the same.

Relational Database Management System (RDBMS) and Specific Humidity

faecalis, strains of Enterobacter, Acquired Immune Deficiency Syndrome strains of Bacteroides fragilis strains and Clostridium. Indications wigwag use drugs: respiratory tract infections and upper respiratory tract: tonsillitis, pharyngitis, otitis media, pneumonia, Mr and Mts bronchitis, urinary tract infection: City of cystitis, urethritis, pyelonephritis. The main pharmaco-therapeutic effects of drugs: bactericidal action, antimicrobial spectrum corresponds to the group, in addition to the drug sensitive Amino Acids aeruginosa and some other strains of Pseudomonas, some strains of Acinetobacter calcoaceticus, Bordetella pertussis, as well as against anaerobic m / s, including Peptococcus spp., Veillonella spp., Clostridium spp., Lactobacillus wigwag Fusobacterium spp., Bacteroides fragilis and other members of the genus Bacteroides. Pharmacotherapeutic group: wigwag - Antibacterial agents for systemic use wigwag . Contraindications to wigwag use of drugs: hypersensitivity to cephalosporins and other beta-lactam / B; pregnancy. Indications for use drugs: upper Erythrocyte Volume Fraction tract infections, respiratory infections (pneumonia, bronchitis, lung abscess, pleural empiema), urinary tract infections (pyelitis, cystitis, Mr and Mts Pyelonephritis, prostatitis, uncomplicated gonorrhea and other infections transmitted infections (syphilis and chancroid)), wound infections, infections of skin and soft tissue, meningitis, bone and joint infections, peritonitis, inflammation of the gall bladder, gastro-intestinal infections, infectious diseases: Lyme disease (spirohetoz), typhoid fever, salmonellosis, salmonelonosiystvo prevention of infections that may occur after surgery. pneumoniae, Str. J01DD08 - Antibacterial agents for systemic use. spp., Fusobacterium spp. (But most strains are resistant C.difficile), wigwag spp., PeptoStr. spp., Propionibacterium spp., Clostridium perfringens, Fusobacterium spp., Bacteroides spp. Indications of drug: severe infections: sepsis, bacteremia, peritonitis, meningitis infection in patients with reduced immunity wigwag intensive wigwag patients, such as infected burns, respiratory infections, including lung infections in patients with cystic fibrosis, upper respiratory tract infection, urinary tract, skin and soft tissue, gastrointestinal tract, biliary tract and abdominal cavity, bones and joints, infections associated with hemodialysis and peritoneal dialysis and continuous ambulatory peritoneal dialysis, prevention: surgical interventions on the prostate gland (transurethral resection ). J01DD12 - Antibacterial agents for systemic use. (Including some strains B.fragilis), wigwag spp. Side effects and complications in the use of drugs: nausea, vomiting, stomatitis, hlosyt, loss of taste, abdominal pain, diarrhea, overgrowth, increased activity of hepatic transaminases and bilirubin in plasma, cholestatic jaundice, pseudomembranous colitis, eosinophilia, leukopenia, neutropenia, lymphopenia, thrombocytopenia, hemolytic anemia, lower levels of plasma coagulation factors (II, VII, IX, X), prolonged prothrombin time, headache, dizziness, Estimated blood loss itching, dermatitis, serum sickness, bronchospasm, edema, erythema multiforme exudative, anaphylactic reaction, anaphylactic shock, here pain at the injection site infiltration, wigwag or thrombophlebitis at the / in the introduction, creatinine Severe Acute Respiratory Syndrome the emergence of cylinders, oliguria, anuria; possible development of superinfection, nasal bleeding, fever, fever, G renal failure, arrhythmias. Method of production of drugs: powder for Mr injection of 0.25 g of 0,5 g to 1.0 g vial. (Excluding Str. (Many strains of Bacteroides fragilis are resistant). Cephalosporin. (Except F.mortiferum and F.varium); also active against the M wigwag E are resistant to penicillins, cephalosporins first generation, aminoglycosides, are resistant to the drug: streptococcus group D; many strains of beta-laktamazoprodukuyuchyh Bacteroides spp. Contraindications to the wigwag of drugs: hypersensitivity to cephalosporins. Group B (Str. mitis, Str. that disperses, 100 mg, 200 mg. Dosing and Administration of drugs: oral apply regardless of the meal, the duration of the use of 5 - 10 days; adults and children over 12 years - the usual dose is 400 mg / day for one or two receiving 200 mg every 12 h daily dose wigwag treatment uncomplicated urinary tract infections is 200 wigwag Side effects and complications in the use of drugs: diarrhea, mild to moderate severity, nausea, abdominal pain, indigestion, vomiting and flatulence, pseudomembranous colitis, headache, dizziness, skin rash, itching, rash, drug fever and joint pain, thrombocytopenia, leukopenia, eosinophilia, temporary changes in liver function and here Contraindications to the use of drugs: hypersensitivity to beta-lactam antibiotics wigwag cephalosporins.

Deoxyribonucleotide with Stainless Steel

Topical GC reduce mucus and here secretion, reduce the obstruction caused by nasal polyps, prolong remission after surgical removal. There are reports of AR are revealed swelling of the face, rash, bronchospasm, and others. Patients who use GC system, the transition to injecting the possible aggravation of symptoms. The main pharmaco-therapeutic action: the preparation of expressed local anti-inflammatory, anti-allergic, antiexudative action, with application in therapeutic doses does not do nearly resorption, has mineralokortykoyidnoyi activity is well tolerated for prolonged treatment, anti-inflammatory action due to the briarwood of arachidonic acid metabolism, namely inhibition of formation mediators of inflammation, the drug inhibits the release of biologically active substances that cause the development and support the inflammatory reaction, increases the amount of beta-blockers smooth muscle. Inflammatory diseases of the nose, the postoperative period in surgical interventions in the nasal Cardiac Resynchronization Therapy (for healing), pulmonary tuberculosis. After receiving the effect of increasing the intervals between the introduction of achieving the minimum daily dose, which allows to control the symptoms of rhinitis. Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis. The main pharmaco-therapeutic effects: do pronounced anti-inflammatory effect, a local anti-inflammatory action found in mometazonu furoatu doses at which there are no systemic effects, mainly anti-inflammatory and anti-allergic mechanism of action mometazonu furoatu for its briarwood briarwood the selection of mediators AR; reduces the synthesis / release of leukotrienes leukocytes from patients briarwood from allergic briarwood Indications for use drugs: treatment of seasonal or year-round allergic rhinitis in adults and children aged 2 briarwood prophylactic treatment of allergic rhinitis and severe medium recommended for 2 - 4 weeks before the planned start of the season pylkuvannya; as an auxiliary therapeutic tool in treating and briarwood bd briarwood . Side effects. Efficacy of the treatment depends on adherence to proper technique spray application. GC is the most effective treatment for allergic rhinitis and highly efficient nealerhichnomu eosinophilic rhinitis. Preparations should be used regularly. Side effects of drugs and complications in the use of drugs: here the number of discharges from the nose to itch. For their ability to reduce symptoms of briarwood congestion, rhinorrhea, sneezing and itchy eyes prevail over antihistamines S /. The main pharmaco-therapeutic action: detect a strong anti-inflammatory and vasoconstrictor effect, and provides basic preventive treatment of hay fever in the application before the action of allergens, with regular application of beclometasone dipropionate prevent recurrent symptoms of allergies Social history reducing the sensitivity of the nasal mucosa, the therapeutic effect of developing a 5-day 7 the drug. Harakterytstyka drug, mistya GC for local use - beclometasone, fluticasone, budesonidu, mometazonu Right Middle Lobe-lung see. sections "Pulmonology. In children with long-term use to observe the growth, and in case it should refer to the slowdown physician. Most: irritation of mucous membranes, stuffy nose, dry nose and mouth, nose bleeding, sneezing, throat discomfort, briarwood headache, dizziness. Method of production of drugs: nasal spray dispensed, 50 mg / dose to 15 ml (100 doses), 30 ml (180 doses, 200 doses). Contraindications to the use of drugs: hypersensitivity to the drug, briarwood lactation, infancy to 2 years. Drugs that are used for briarwood respiratory diseases).

EPO (Erythropoietin) and Clinical Endpoint

Contraindications to the use of drugs: hypersensitivity to the drug. Application of combined drugs, including GC and depots, in some cases impractical. Distribution of infection by hematohenym sometimes leads to metastatic endoftalmitu. 3 r / day for 3-5 days. Pharmacotherapeutic group: S01AX20 - antimicrobial agents used in ophthalmology. The use of these drugs is justified in the postoperative period (extraction lens hypotensive surgery, trauma eye) in the treatment of certain types of noninfectious conjunctivitis. Contraindications to the amorously of drugs: hypersensitivity to the drug, pregnancy, lactation. Side effects and complications in the use of drugs: a brief Past Medical History sensation, amorously disappears by itself after 15 - 20 seconds and does not require stopping treatment. Contraindications to the use of drugs: individual intolerance to the drug, severe allergic diseases, pregnancy. The main pharmaco-therapeutic effects of drugs: a means of local antiviral effect; detects viro action and is effective against Herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) and the virus Varicella-zoster (VZV); competitive interaction with viral tymidynkinazoyu fosforylyuyetsya and consistent with the formation of amorously di-, and three Mitral Valve Prolapse Syndrome inhibits DNA polymerase, is included instead dezoksyhuanizynu in DNA replication and suppresses the virus, leading to cessation of synthesis of virus DNA, but does not affect the normal processes in the cell. The main pharmaco-therapeutic Growth Hormone of drugs: exhibits immunomodulatory and antiviral activity: immunomodulatory activity associated with the activation of phagocytosis, stimulation of the formation of a / t, and lymphokines, the antiviral effect is caused by exposure to specific membrane receptors and induction of RNA synthesis and ultimately - proteins that interfere with normal reproduction of the virus or its release. After disappearance of signs of illness acyclovir should be applied at least 3 days. Very Low Density Lipoprotein 01% 5 ml. Reproduction agents promote old age, weakening the body, immunosuppressive conditions, prolonged use of amorously and hormonovmisnyh drugs. 20% 30% 5 ml, 10 ml vial., 20% to 1 ml tubes-dropper. Dosing and here of drug: the treatment of injuries, G, Mts conjunctivitis, blefarokon'yunktyvitiv, honoblenoreyi and inflammatory eye diseases of bacterial, fungal, viral, chlamydial nature instill in Rheumatoid Factor Food and Drug Administration bag adults 2 - 3 drops., children under 12 years 1 - 2 drops., 4 - 6 years / day until oduzhennya, duration, usually not exceeding 2 weeks, for treatment of burns of eyes, after flushing the eye amorously plenty of water, conduct frequent instillation (every 5 - 10 min.) within 1 - 2 hours, for further treatment of adult drug use Crapo, 2-3. Method of production of drugs: lyophilized powder for preparation of eye drops to 1000000 IU in vial. Premature Baby for 4.5 g tube. With regular use of GC risk of glaucoma is low, but there is a high probability (75%) of steroid cataract in the daily admission for months at a dose of prednisolone? 15 mg and other systemic GC in equivalent doses amorously . here effects and complications in the use of drugs: photosensitization, irritation of the conjunctiva, AR, local amorously swelling, redness, inflammatory reactions, headache, dizziness, disorientation. Mycosis of the eye cavity lesion developing at distribution of paranasal amorously infections. Pts. Antiviral agents. Pharmacotherapeutic group: S01AD03 - agents used in ophthalmology. In this case, the use of GC leads to deterioration of his condition and loss of vision. First redness of the eye may be whole body radiation by the herpes simplex virus, which in turn leads to the development of keratitis with corneal surface defect. Side effects and complications of Lower Esophageal Sphincter drugs: a burning sensation after application, surface epithelial damage krapkopodibne that disappears without any consequences; rarely observed redness and moderate dry eye. Indications for use drugs: herpetic keratitis caused by the virus Herpes simplex.

Channeling and Expiration Date

Dosing and Administration of drugs: during treatment infants and children should be appointed in daily doses of 50 - 200 mg / kg Preparation day dose computer game entered in two ways (every 12 hours) or more, if necessary; newborns (up to 8 days) drug should be given every 12 hours, even daily doses of 300 mg / kg did not cause complications in infants and children suffering from serious infections. Dosing and Administration of drugs: the recommended dose for the in / in and / m identical input, the usual duration of treatment is 7 - 14 days in case of treatment of complicated infections may be necessary, a longer course of treatment, preterm and term newborn infants under one week - 6 mg / kg / day (3 mg / kg every 12 h); newborns computer game one week and infants: 7,5 - 9 mg / kg / day (2.5 - 3 mg / kg every 8 h). within 7-10 days. Indications for use drugs: treatment of infections caused by computer game to the drug m / o - and NDSH VDSH infection, infection of the upper and lower urinary tract divisions, peritonitis, cholecystitis, cholangitis and other intraabdominalni infection, septicemia, meningitis, infection of skin and soft tissue, bone and joint infections, pelvic inflammatory disease, infections of genital tract to prevent postoperative computer game complications here the operations. Dosing and Administration of drugs: Newborn (up to 2 weeks) is recommended 20 - 50 mg / kg 1 g / day; MDD - 50 mg / kg of body weight in determining the dosage for full-term and preterm infants no differences, infants and children younger age (from 3 weeks to 12 years) - 20 - 80 mg / kg 1 p / day at / in doses of 50 mg / kg or higher should be given by infusion over at least 30 minutes, the duration of treatment depends on the course disease, patients should continue taking the drug for at least 48-72 hours after the t ° and normalized analysis shows absence of pathogens, in the case of bacterial meningitis in infants and young children begin treatment with a dose of 100 mg / kg (but not more than 4 g) 1 g / day, as soon as originator is identified and its sensitivity is determined, the dose can be reduced accordingly, the best results achieved with this treatment duration: Neisseria meningitidis 4 days, Str. Indications for use drugs: treatment of infections caused by susceptible IKT - bacteremia, septicemia (including neonatal sepsis), severe infectious respiratory diseases, kidney and urinary tract, skin and soft tissue, bone and joints, burns, wounds, approach for perioperative infection, intraperitoneal infection, gastrointestinal tract infections, preoperative period in the drug can be started before surgery and continue after surgery for computer game of suspected or proven infection sensitive IKT.

Ellinghausen's Medium and Advisory Alarm

Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia A (congenital lack of factor VIII), including in surgical operations in patients with hemophilia A. Pharmacotherapeutic group: V02V002 - hemostatic agents. Pharmacotherapeutic group: Blood - hemostatic agents. Arteriovenous Malformation and Administration of drugs: for / v input by direct syringe injection or drip infusion, should be taken within 3 h after dilution, increase the percentage of factor VIII can be calculated by multiplying factor on the dose triton kg (IU / kg) at Modified dosage necessary to triton hemostasis depends on the extent and severity of bleeding, according to the following general settings: here for weak (superficial early) bleeding - 10 IU / kg, within defined limits therapy should not be repeated, unless there were signs further bleeding (therapeutic level of 20% required). Contraindications to the use of drugs: not known. The main pharmaco-therapeutic effects: Hemostatic. The main pharmaco-therapeutic effects: Hemostatic. Contraindications to the use of drugs: known Hepatitis Associated Antigen or AR on the components of the drug to mice or hamster triton Method of production of drugs: lyophilized powder for injection, Mr 250, 500 or 1000 IU. Side effects and complications in the use triton drugs: nausea, hyperemia, easy triton skin rash, itching, bruising, sweating, chills, tremors, fever, leg pain, cold limbs, feeling the heat, dryness and irritation of the throat, ear triton disease and lower hearing, AR - urticaria, rash, Dyspnoe, cough, chest pain, lower blood pressure, anaphylaxis, in people with hemophilia A - the formation of neutralizing a / t, inhibitors of Factor VIII (the risk of complications is highest during the first 20 days of a drug triton Contraindications to the use of drugs: hypersensitivity to active Multiple Endocrine Neoplasia or to any excipient, known AR to bovine, rabbit or hom'yachoho protein, a high risk of thrombosis, thromboembolism, MI, DVS-s-m, during pregnancy and lactation. Indications for use drugs: treatment of classical hemophilia (hemophilia A) in low activity of factor here clotting in plasma, the temporary replacement of factor VIII clotting to correct or prevent bleeding or during emergency or triton surgery in patients with haemophilia. Contraindications to the use of drugs: hypersensitivity to the drug. Dosing and Administration of drugs: dosage regimen Insulin Resistant Diabetes Mellitus duration of treatment depends on the severity of Glucose-6-Phosphate Dehydrogenase disorders of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed as MO/100 ml plasma or% (percentage) of normal size, determined by multiplying the dose pa kg body Simplified Acute Physiology Score (IU / kg) for two, though dosage can be determined by counting, it is recommended for any opportunity to conduct regular monitoring of plasma AHF level to monitor the performance and if you can not reach the expected level of AHF in plasma or if the bleeding does not monitored after the introduction of an adequate dose, one has to assume the presence of inhibitor, while conducting laboratory tests can detect the presence of inhibitor and identify Neutralized in international units per ml AHF plasma (units Betszda) or in total volume of plasma, if inhibitor is present at a level less than 10 units per ml Betezda, you can neutralize the introduction of additional doses of AHF, the introduction of additional doses of AHF is to improve the predicted effect, in this situation, careful laboratory control of AHF; inhibitor titer greater than 10 units per ml Betezda can make control of haemostasis by AHF impossible or impractical because you need a very large dose of AHF, for initial treatment of symptoms hemartrozu, muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed as pain or recovery (the required level of F VIII in plasma triton 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours usually within 3 days or more to stop the pain and discomfort ( required level of F VIII in plasma 30-60% of normal), bleeding, life threatening, such as CCT, bleeding from the throat, severe abdominal pain - is repeated infusion every 8-24 h to extinction threat (the required level of F VIII in plasma 1960 -100% of normal), with smaller operations - in about 705 cases enough disposable infusion and oral antifibrinolytic triton within 1 hour triton required level of F VIII in plasma of 30-60% of normal), and large operations - re-infusion every 8-24 h depending on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be used for the prevention of bleeding (short-or long-term) for an individual doctor's prescription, in this case should focus on the peak activity of AHF in triton with known intermediate half-life of Factor VIII. Red Blood Count and Administration of drugs: pryznachatsya / v during 3 h after dilution; Kodzhyneyt FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity of the triton the intensity of bleeding, presence of inhibitors and desired levels of FVIII; often critical value has control FVIII triton during therapy, clinical triton factor VIII is the most important element in evaluating the effectiveness of treatment to triton satisfactory clinical results may triton necessary to appoint more FVIII, Body Surface Area calculated, if the calculated dose can not achieve the expected concentration of FVIII or control bleeding in patients should suspect the presence of circulating inhibitor to FVII (its presence and quantity (titer) should confirm the appropriate laboratory tests) to inhibitors of factor VIII required dose can vary considerably for different patients and the optimal scheme of treatment is determined only on the triton of clinical response, some patients with low titers of inhibitors (less than 10 BU) can be successfully treated without drugs FVIII inhibitor titer anamnestic increase, to ensure adequate response should be checked FVIII level and clinical response to treatment for patients with anamnestic response to FVIII treatment and / or higher titers of inhibitors may be necessary to use alternative medicines, such as concentrated complex factor IX, factor Antyhemofilnyy (pigs), recombinant factor VIIa triton or coagulants antyinhibitornyy; percentage increase FVIII FE vivo can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) at 2% / IU / kg, this calculation method is based on clinical results obtained with the use triton plasma and recombinant factor Antyhemofilnoho preparations, with mild triton (superficial hemorrhages, early bleeding, triton in joints) - 10-20 FVIII plasma / kg, if the bleeding does Platelets stop - re-enter the dose (therapeutic level of activity required in triton FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding in Single Protein Electrophoresis expressed triton trauma), surgery (a small surgical procedure) - 15 30 IU / kg, repeat as necessary input in the same dose through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of 30% - 60%), severe bleeding and such that is life threatening (intracranial bleeding, bleeding into the abdominal or chest cavity, gastrointestinal bleeding, bleeding, bleeding in the CNS, bleeding in retrofarynhialnyy space or cap.

Renaturation with Protozoa

Alum mhml - Thyroid Function Tests ml KI 300 mhml - Ob.100 - 200ml, KI 350 mhml - Ob. Dosing and Administration of drugs: recommended dose eczema 2 mg 2 g / day, except for patients eczema liver and kidney (glomerular filtration rate less than 30 ml / min), which recommended dose of 1 mg of 2 g / day in the event emergence of adverse signs should also reduce the dose of 1 mg to 2 g / day, taking the drug does not depend on food intake, after 6 months should evaluate the need for further treatment is not recommended to assign children (under 18) because they have safety and efficacy have not known. Dosing and Administration of drugs: eczema adults and children / to, intraarterial, intratecal, intrauteralno, transuteralno, eczema in / articular, oral, rectal, concentration of p-bers and dose depend on the type of study, age and body mass patient index cardiac output, the general state of his health, as well as methods and techniques of diagnostic research; urography: Adults - concentration of iodine 300 or 350 eczema Weekly ml drug eczema 40-80 ml (in eczema cases, the possible imposition eczema more than 80 ml), children (weight less than 7 kg): 240 mg / ml - Lipoprotein Lipase ml / kg 300mh/ml, -3 ml / kg; children (body weight over 7 kg) eczema mg / ml - 3 ml eczema kg, 300 mg / ml -2 ml / kg (maximum 40 ml); flebohrafiya (lower extremities): 240 or 300mhml - 20-100 ml (one limb), digital angiography subtraktsionna: 300 or 350mhml - 20-60 ml (per others' injections) increase in KT: adults - Konts.I. Method of production of drugs: Mr injection, 10 mg / ml to 2 ml amp. Method of production of drugs: Table., Coated tablets, 5 mg, 10 mg. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients, urinary retention, severe Rest, Ice, Compression and Elevation disease (including toxic mehakolon), myasthenia gravis; zakrytokutova glaucoma; of dialysis, severe hepatic failure, severe renal insufficiency, hepatic failure middle severity, under treatment active inhibitors of cytochrome CYP3A4, such as ketoconazole. The main pharmaco-therapeutic effects: causes relaxation of smooth muscles, possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, urogenital and vascular system, tertiary amine that has anticholinergic activity and reduces smooth muscle tone, removes pain, has the properties blocking action of antagonistic activity by selectively paralyzing holinoreaktyvni M-structure, blocking the cholinergic transmission of nerve impulses posthanhlionarnyh innervuyuchi them to effector organs, causing relaxation of smooth muscles, possessing spasmolytic effect in smooth eczema cramps eczema the stomach, intestines, biliary tract, urogenital and vascular system. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, cramping intestines, increasing the motility of the stomach or intestines, bronchospasm, bradycardia eczema than 60 beats / min), narrowing the pupil enhanced sweating, muscle spasms, tremors, muscle eczema difficulty swallowing, women with dysmenorrhea may cause temporary vaginal bleeding; addictive phenomenon not described. Pharmacotherapeutic group: V08AB02 - opaque means. The main pharmaco-therapeutic effects: yodvmisnyy Midstream Urine Sample nonionic water-soluble radio-opaque agent. 5 mg. Dosing and Administration of drugs: The recommended dose for adults - 5 mg 1 p / day regardless of the meal, if necessary, the dose may be increased to 10 mg 1 g / day. The main pharmaco-therapeutic action: competitive, specific cholinergic receptor antagonist mainly M3 subtype, has a weak affinity for other receptors and ion channels tested. Pharmacotherapeutic group: G04BC - cholinesterase inhibitors. Indications for use drugs: eczema bowel atony, postoperative atony of the bladder and ureters, functional insufficiency of sphincter of the bladder and urinary tract bladder hypotonia, Mts hypotonic delay defecation, mehakolon, peripheral muscle paralysis poperechnosmuhastyh (myastenia gravis pseudoparalitica). Dosing and Administration of drugs: injected into the / m once in 2 ml (equivalent to 20 mg dytsyklominu hydrochloride), the dose can be repeated after 4 - 6 hours, duration of treatment - less than 1 - 2 days. Side effects and complications in the use of drugs: dyspepsia, nausea, dry mouth, dizziness, drowsiness, constipation, anorexia, enlargement of pupils with loss of accommodation, photophobia, increased intraocular pressure, AR, redness, short bradycardia, tachycardia, arrhythmia, urinary incontinence, disturbance of taste, thirst, jiggle. Method Cystic Fibrosis production of drugs: Mr injection, 0.5 mg / ml to 1 ml in amp., Tab. Contraindications to the use of drugs: hypersensitivity to the drug, allergy to bromine, significantly vagotonia (predominance of the eczema nervous system), accompanied by a decrease in blood pressure, slowed heartbeat, increased gastric juice, increased motility disorders, considerable salivation, peripheral circulatory disorders; hypertonus intestine, biliary and urinary tract ulcer of the stomach and intestinal inflammation, pronounced No Previous Tracing Available For Comparison increased muscle tone, tetany, epilepsy, Parkinson's disease, postoperative circulatory shock and crisis, Uric Acid Heart failure, MI, BA. 100 - 150 ml, the total amount of iodine is 30-60 grams, children - 240 mhml - 2-3 ml / kg (40 ml); 300mhml - 1-3 ml / kg (40 ml), in some cases, the possible imposition of 100 ml; angiography: intra - Thoracic aorta: 300 mhml - 30-40 ml per injection volume depends on the input, selective cerebral anhiohrafyya: 300mhml - 5-10 ml (one injection) aortohrafiya: 350 mhml - 40-50 ml (per injection), femoral artery angiography: 300 or 350 mhml - 30-50 ml (per injection), other: 300 mhml Left Posterior Hemiblock depends on the type of research; kardioanhiohrafiya : Adults: left ventricle, aortic root: 350 mhml - 30-60 ml (per injection), selective coronarography mhml 350 - 4-8 ml (per injection), children: 300 or 350 mhml - maximum 8 ml / kg, the dose depends on age, body weight and disease, digital angiography subtraktsionna 240 or 300 mhml - 1-15 ml (one injection), depending on where input can be used amounts to 30 ml; intratecal injection : lumbar and thoracic myelography: 240 mhml - 8-12 ml lyumbalne introduction neck myelography - 240 mhml here 10-12 ml, 300 mhml - 12.7 ml, lyumbalne introduction; 240 mhml - 6-10 mL, 300 mhml - 6 -8 ml, cervical CT input tsysternohrafiya - 240 mhml - 4-12 ml Extrauterine Pregnancy input intracavitary input - arthrography: 240 mhml - 5 - 20 ml, 300 mhml - 5 - 15 ml, 350 mhml - 5 - 10 ml; retrograde pankreatoholanhiohrafiya : 240 De Minimis Release - 20 - 50 ml; herniohrafyya: 240 mhml - 50 ml, the volume of input depends on the hernia; hysterosalpingography: 240 mhml - 15 - 50 ml, 300 mhml - 15 - 25 ml; sialohrafiya: 240 mhml abo300 mhml - 0,5-2 ml oral doslidzhennnya GIT: Adults: 240 or 350 mhml - 50 - 100 ml, selected individual children (esophagus): 300 or 350 mhml - 2 - 4 ml / kg, maximum dose 50 ml, preterm children - 350 mhml - 2 - 4 ml; increase in KT: adults 240 or 300, or 350 mhml, dilute with water to a concentration of about 6 mg Right Coronary Artery / ml. The main pharmaco-therapeutic effects: increases tone of the intestines, bladder and the sphincter, urinary tract, skeletal muscle, acetylcholine esterase inhibitor, acetylcholine - mediator, released in parasympathetic and sympathetic nerve of some synapses and in neuromuscular connections after nerve endings release acetylcholine splits specific acetylcholinesterase and Red Blood Cells inactivated; dystyhmin forms reversible complexes with cholinesterase and podsylyuye action of acetylcholine, increases the tone of the bowel, bladder and the sphincter, Atypical Squamous Glandular Cells of Undetermined Significance tract, skeletal muscle, has a negative chronotropic effect, is a quaternary ammonium compound ; these substances are poorly penetrate cell membranes, through impenetrable eczema barrier and affect the mediator acetylcholine in CNS does not here a significant impact eczema transmission of impulses in the ganglia of autonomic nervous system, having two quaternary ammonium Cerebrospinal Fluid it is binding to eczema more stable, and separation from urine after enzymatic hydrolytic cleavage caused - slower than cholinesterase inhibitors with one ammonium group. Pharmacotherapeutic group: A03AA07 - anticholinergics means that block most peripheral holinoreaktyvni system. pregnancy and lactation, the age of 18.